Prognostic factors of craniopharyngioma with special reference to autocrine/paracrine signaling: underestimated implication of growth hormone receptor

Ogawa, Yoshikazu; Watanabe, Mika; Tominaga, Teiji

doi:10.1007/s00701-015-2519-0

Cited by 15 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4,47,50,51 GH accelerates tumor progression through autocrine/paracrine effects on cancer cell behavior and neighboring cells within the tumor microenvironment. These effects include promoting cell survival/proliferation, 52,53 migration/invasion, 53,54 oncogenic transformation, 55,56 and epithelial-to-mesenchymal transition, 54,57,58 as well as promoting tumor angiogenesis 59 and lymphangiogenesis 60 and enhancing a cancer stem cell-like phenotype. 57,61 These effects have been observed in multiple tumor types, including breast, endometrial, and hepatocellular carcinomas, and lung cancer, melanoma, prostate cancer, and colon cancer.…”

Section: Gh Excess: Disease Indicationsmentioning

confidence: 99%

Targeting growth hormone function: strategies and therapeutic applications

Flanagan

Langley

et al. 2019

Sig Transduct Target Ther

View full text Add to dashboard Cite

Human growth hormone (GH) is a classical pituitary endocrine hormone that is essential for normal postnatal growth and has pleiotropic effects across multiple physiological systems. GH is also expressed in extrapituitary tissues and has localized autocrine/paracrine effects at these sites. In adults, hypersecretion of GH causes acromegaly, and strategies that block the release of GH or that inhibit GH receptor (GHR) activation are the primary forms of medical therapy for this disease. Overproduction of GH has also been linked to cancer and the microvascular complications that are associated with diabetes. However, studies to investigate the therapeutic potential of GHR antagonism in these diseases have been limited, most likely due to difficulty in accessing therapeutic tools to study the pharmacology of the receptor in vivo. This review will discuss current and emerging strategies for antagonizing GH function and the potential disease indications.

show abstract

Section: Gh Excess: Disease Indicationsmentioning

confidence: 99%

Targeting growth hormone function: strategies and therapeutic applications

Flanagan

Langley

et al. 2019

Sig Transduct Target Ther

View full text Add to dashboard Cite

show abstract

“…identified 10 hub genes for potential application in early diagnosis and therapy for ACP. Several studies have also identified the associations between the prognosis of CP and many biomarkers, including B7-H3 [ 51 ], β-catenin [ 52 ], and growth hormone receptors [ 53 ]. Moreover, another study identified four inflammatory mediators (CXCL6, CXCL10, CXCL11, and CXCL13) as hub genes with great value for targeted therapy in CP [ 54 ].…”

Section: Discussionmentioning

confidence: 99%

The clinical significance of inflammatory mediators in predicting obesity and progression-free survival in patients with adult-onset Craniopharyngioma

Xiao,

Wu,

Liu

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Background Craniopharyngioma (CP) is a rare malformational tumor characterized by high rates of recurrence and morbid obesity. However, the role of inflammatory mediators in obesity and the prognosis of patients with CP remains unknown. Therefore, the present study aimed to analyze associations of inflammatory mediators with weight-related outcomes and the prognosis of patients with CP. Methods A total of 130 consecutive patients with CP were included in this study. The expression levels of seven inflammatory mediators and the plasma leptin concentration were investigated. Clinical parameters, weight changes, new-onset obesity, and progression-free survival (PFS) were recorded. The relationships between inflammatory mediators, clinicopathologic parameters, weight-related outcomes, and PFS were explored. Results Compared with those in normal pituitary tissue, the expressions of inflammatory mediators in tumor tissue were higher. Higher expression levels of CXCL1 and CXCL8 were identified as independent risk factors for significant weight gain, and CXCL1 and TNF were identified as independent risk factors for new-onset postoperative obesity. Poor PFS was associated with higher expression levels of CXCL1, CXCL8, IL1A, IL6, and TNF. Conclusion The present study revealed that inflammatory mediators are associated with morbid obesity in patients with CP. Inflammatory mediators may be the critical bridge between elevated leptin and weight-related outcomes. Additionally, PFS was associated with the expression of inflammatory mediators. Further research is needed to elucidate the underlying mechanisms of inflammatory mediators and their potential as targets for novel therapies for CP.

show abstract

“…Where possible a histological diagnosis should be obtained prior to definitive treatment, unless appearances are clearly typical intraoperatively or in neurosurgical emergencies. No molecular markers correlate with overall (OS) or progression-free survival (PFS) and therefore need not be measured routinely [37][38][39][40][41] .…”

Section: Be Aware That Ki67 Labelling or Ctnnb1 Mutation Analysis Of ...mentioning

confidence: 99%

National UK guidelines for the management of paediatric craniopharyngioma

Gan

Morillon

Albanese

et al. 2023

The Lancet Diabetes & Endocrinology

View full text Add to dashboard Cite

Prognostic factors of craniopharyngioma with special reference to autocrine/paracrine signaling: underestimated implication of growth hormone receptor

Abstract: High expression of GHR is associated with shorter duration of postoperative stable disease in patients with craniopharyngioma. If the surgical specimens were craniopharyngiomas with high GHR expression, GH supplementation would be introduced quite prudently.

Cited by 15 publications

References 27 publications

Targeting growth hormone function: strategies and therapeutic applications

Targeting growth hormone function: strategies and therapeutic applications

The clinical significance of inflammatory mediators in predicting obesity and progression-free survival in patients with adult-onset Craniopharyngioma

National UK guidelines for the management of paediatric craniopharyngioma

Contact Info

Product

Resources

About